O
11.10
-0.04 (-0.36%)
| Previous Close | 11.14 |
| Open | 11.15 |
| Volume | 787,823 |
| Avg. Volume (3M) | 819,501 |
| Market Cap | 761,841,088 |
| Price / Book | 2.21 |
| 52 Weeks Range | |
| Earnings Date | 14 Nov 2025 |
| Diluted EPS (TTM) | -2.00 |
| Total Debt/Equity (MRQ) | 0.30% |
| Current Ratio (MRQ) | 15.22 |
| Operating Cash Flow (TTM) | -124.83 M |
| Levered Free Cash Flow (TTM) | -70.86 M |
| Return on Assets (TTM) | -27.44% |
| Return on Equity (TTM) | -41.59% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Olema Pharmaceuticals, Inc. | Bullish | Bearish |
AIStockmoo Score
-0.5
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.50 |
|
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 3.32% |
| % Held by Institutions | 98.70% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 29.00 (JP Morgan, 161.26%) | Buy |
| Median | 22.00 (98.20%) | |
| Low | 20.00 (Guggenheim, 80.18%) | Buy |
| Average | 24.00 (116.22%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 7.07 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 20 Oct 2025 | 28.00 (152.25%) | Buy | 7.78 |
| Guggenheim | 08 Oct 2025 | 20.00 (80.18%) | Buy | 10.73 |
| Oppenheimer | 03 Sep 2025 | 22.00 (98.20%) | Buy | 6.29 |
| JP Morgan | 14 Aug 2025 | 29.00 (161.26%) | Buy | 5.26 |
| Citigroup | 12 Aug 2025 | 21.00 (89.19%) | Buy | 5.31 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 18 Oct 2025 | Announcement | Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025 |
| 02 Oct 2025 | Announcement | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 03 Sep 2025 | Announcement | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 02 Sep 2025 | Announcement | Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer |
| 20 Aug 2025 | Announcement | Olema Oncology to Participate in Upcoming Investor Conferences |
| 14 Aug 2025 | Announcement | Biotech Stocks Rally as Oncology Market Targets $866B by 2034 |
| 11 Aug 2025 | Announcement | Olema Oncology Reports Second Quarter 2025 Financial and Operating Results |
| 04 Aug 2025 | Announcement | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |